NCT06802926 Pilot Trial of Colchicine for Graft Failure in CABG
| NCT ID | NCT06802926 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Ruijin Hospital |
| Condition | CABG |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-29 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2025-12-29 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pilot trial is to to evaluate the preliminary effect of oral colchicine therapy on graft outcomes in patients underwent primary isolated CABG. The main questions it aims to answer is: 1. Whether the oral colchicine therapy may reduce the failure outcome of grafts after CABG. 2. Whether it is feasible to construct a muticenter powered trial to test the superiority hypothesis. Researchers will compare colchicine to none to see if colchicine works. Participants will 1. Take oral colchicine (0.5mg daily) therapy for 12 months after CABG. 2. Clinical follow-up at Month 1, 6, and 12 after CABG. 3. Protocol-driven CCTA at Week 1 and Month 12 after CABG.
Eligibility Criteria
Inclusion Criteria: * Age≥18 years old， * Any sex， * Signed informed consent， * Within 3 days after a successful isolated CABG Exclusion Criteria: * Allergy, * Hematopoietic dysfunction, * Moderate to severe hepatic dysfunction, * Moderate to severe renal dysfunction.
Contact & Investigator
Qiang Zhao, MD
STUDY CHAIR
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
Frequently Asked Questions
Who can join the NCT06802926 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying CABG. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06802926 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06802926 currently recruiting?
Yes, NCT06802926 is actively recruiting participants. Contact the research team at zyp12220@rjh.com.cn for enrollment information.
Where is the NCT06802926 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06802926 clinical trial?
NCT06802926 is sponsored by Ruijin Hospital. The principal investigator is Qiang Zhao, MD at Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China. The trial plans to enroll 100 participants.